Last Updated : May 17, 2018
Details
FilesGeneric Name:
latanoprost
Project Status:
Complete
Therapeutic Area:
glaucoma and ocular hypertension
Manufacturer:
Laboratoires Théa
Call for patient/clinician input open:
Brand Name:
Monoprost
Project Line:
Reimbursement Review
Project Number:
SR0541-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
glaucoma and ocular hypertension
Date NOC Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
Key Milestones2 |
|
|---|---|
| Call for patient input posted | September 26, 2017 |
| Patient group input closed | November 15, 2017 |
| Clarification:
- No patient input submission received |
|
| Submission received | October 25, 2017 |
| Submission accepted for review | November 08, 2017 |
| Review initiated | November 09, 2017 |
| Draft CDR review report(s) sent to applicant | February 01, 2018 |
| Comments from applicant on draft CDR review report(s) received | February 12, 2018 |
| Redaction requests from applicant on draft CDR review report(s) received | February 20, 2018 |
| CDR review team's comments on draft CDR review report(s) sent to applicant | March 09, 2018 |
| Canadian Drug Expert Committee (CDEC) meeting | March 21, 2018 |
| CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plans | April 03, 2018 |
| Embargo period ended and validation of redacted CDR review report(s) received | April 17, 2018 |
| CDEC Final Recommendation issued to applicant and drug plans | April 24, 2018 |
| CDEC Final Recommendation posted | April 27, 2018 |
| Final CDR review report(s) and patient input posted | May 17, 2018 |
Files
Last Updated : May 17, 2018